ATE509622T1 - Amphetamin-ornithine konjugate sowie herstellungs-und verwendungsverfahren - Google Patents
Amphetamin-ornithine konjugate sowie herstellungs-und verwendungsverfahrenInfo
- Publication number
- ATE509622T1 ATE509622T1 AT07869098T AT07869098T ATE509622T1 AT E509622 T1 ATE509622 T1 AT E509622T1 AT 07869098 T AT07869098 T AT 07869098T AT 07869098 T AT07869098 T AT 07869098T AT E509622 T1 ATE509622 T1 AT E509622T1
- Authority
- AT
- Austria
- Prior art keywords
- amphetamine
- conjugates
- ornithine
- disclosed
- production
- Prior art date
Links
- 229960003104 ornithine Drugs 0.000 title 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 229940025084 amphetamine Drugs 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Superconductors And Manufacturing Methods Therefor (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86937506P | 2006-12-11 | 2006-12-11 | |
| PCT/US2007/087028 WO2008073918A1 (en) | 2006-12-11 | 2007-12-10 | Non-standard amino acid conjugates of amphetamine and processes for making and using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE509622T1 true ATE509622T1 (de) | 2011-06-15 |
Family
ID=39512105
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT07869098T ATE509622T1 (de) | 2006-12-11 | 2007-12-10 | Amphetamin-ornithine konjugate sowie herstellungs-und verwendungsverfahren |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US7776917B2 (OSRAM) |
| EP (1) | EP2101571B1 (OSRAM) |
| JP (1) | JP2010512413A (OSRAM) |
| CN (1) | CN101594778A (OSRAM) |
| AT (1) | ATE509622T1 (OSRAM) |
| AU (1) | AU2007333105A1 (OSRAM) |
| BR (1) | BRPI0720105A2 (OSRAM) |
| CA (1) | CA2672138A1 (OSRAM) |
| ES (1) | ES2364865T3 (OSRAM) |
| IL (1) | IL198930A0 (OSRAM) |
| WO (1) | WO2008073918A1 (OSRAM) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060014697A1 (en) * | 2001-08-22 | 2006-01-19 | Travis Mickle | Pharmaceutical compositions for prevention of overdose or abuse |
| DK2018160T3 (da) | 2006-03-16 | 2012-02-06 | Tris Pharma Inc | Modificeret depotformuleringer indeholdende lægemiddel-ionbytterharpikskomplekser |
| AU2007333105A1 (en) * | 2006-12-11 | 2008-06-19 | Kempharm, Inc. | Non-standard amino acid conjugates of amphetamine and processes for making and using the same |
| WO2008098151A2 (en) | 2007-02-08 | 2008-08-14 | Kempharm, Inc. | Polar hydrophilic prodrugs of amphetamine and other stimulants and processes for making and using the same |
| DE102007037478B3 (de) | 2007-08-08 | 2008-04-30 | Leifheit Ag | Wäschetrockenständer |
| WO2010148305A1 (en) * | 2009-06-19 | 2010-12-23 | Cambrex Charles City, Inc. | Methods and compositions for preparation of amphetamine conjugates and salts thereof |
| US20130059914A1 (en) | 2010-04-21 | 2013-03-07 | Signature Therapeutics, Inc. | Compositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof |
| US8779191B2 (en) | 2010-12-20 | 2014-07-15 | Cambrex Charles City, Inc. | Methods and compositions for preparing lisdexamfetamine and salts thereof |
| PH12014500049A1 (en) * | 2011-07-28 | 2016-07-29 | Kempharm Inc | Methylphenidate-prodrugs, processes of making and using the same |
| AU2011374269A1 (en) * | 2011-07-29 | 2014-02-20 | Shire Llc | Homoarginine prodrugs and/or conjugates of amphetamine and other stimulants and processes for making and using the same |
| EP2872161B1 (en) | 2012-06-26 | 2020-12-16 | Del Mar Pharmaceuticals | Dianhydrogalactitol for use in treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations |
| US20140073589A1 (en) * | 2012-06-27 | 2014-03-13 | Shire Ag | Amphetamine Prodrugs |
| EP3530268B1 (en) | 2012-10-09 | 2021-12-15 | Attentive Therapeutics, Inc. | Therapeutic treatment |
| GB2545368B (en) | 2014-10-20 | 2021-04-21 | Elysium Therapeutics Inc | Diversion-resistant opioid formulations |
| US20170056352A1 (en) | 2015-08-25 | 2017-03-02 | Rgenix, Inc. | PHARMACEUTICALLY ACCEPTABLE SALTS OF beta-GUANIDINOPROPIONIC ACID WITH IMPROVED PROPERTIES AND USES THEREOF |
| US11590228B1 (en) | 2015-09-08 | 2023-02-28 | Tris Pharma, Inc | Extended release amphetamine compositions |
| US10335406B2 (en) | 2015-10-01 | 2019-07-02 | Elysium Therapeutics, Inc. | Opioid compositions resistant to overdose and abuse |
| GB2556817B (en) | 2015-10-01 | 2019-11-06 | Elysium Therapeutics Inc | Polysubunit opioid prodrugs resistant to overdose and abuse |
| EP3541362B1 (en) | 2016-11-15 | 2025-11-05 | Klaria Pharma Holding AB | Alginate film comprising a triptan |
| BR112019011640B1 (pt) | 2016-12-11 | 2021-08-17 | Kempharm, Inc | Compostos conjugados de d-metilfenidato, composições que compreendem os mesmos e kit farmacêutico que compreende as ditas composições |
| WO2018160178A1 (en) | 2017-03-01 | 2018-09-07 | Rgenix, Inc. | Pharmaceutically acceptable salts of b-guanidinopropionic acid with improved properties and uses thereof |
| CA3056239C (en) | 2017-03-17 | 2023-09-12 | Elysium Therapeutics, Inc. | Polysubunit opioid prodrugs resistant to overdose and abuse |
| US20200155687A1 (en) * | 2017-04-10 | 2020-05-21 | Shire Pharmaceuticals Inc. | Methods of treatment using an amphetamine prodrug |
| GB201709141D0 (en) | 2017-06-08 | 2017-07-26 | Klaria Pharma Holding Ab | Pharmaceutical formulation |
| US12458592B1 (en) | 2017-09-24 | 2025-11-04 | Tris Pharma, Inc. | Extended release amphetamine tablets |
| US11590081B1 (en) | 2017-09-24 | 2023-02-28 | Tris Pharma, Inc | Extended release amphetamine tablets |
| US20200323797A1 (en) * | 2017-10-06 | 2020-10-15 | Instituto De Medicina Molecular | Treatment of Obesity-related Conditions |
| US12459965B2 (en) | 2017-10-09 | 2025-11-04 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| WO2019199731A1 (en) * | 2018-04-10 | 2019-10-17 | Shire Pharmaceuticals Inc. | Amphetamine prodrug and crystalline froms thereof |
| GB201808462D0 (en) * | 2018-05-23 | 2018-07-11 | Klaria Pharma Holding Ab | Pharmaceutical formulation |
| EP3934635A4 (en) * | 2019-03-06 | 2022-12-07 | Ensysce Biosciences, Inc. | COMPOSITIONS OF ENZYME-CLEAVABLE AMPHETAMINE PRODRUGS AND INHIBITORS THEREOF |
| JP2022529353A (ja) | 2019-04-17 | 2022-06-21 | コンパス パスファインダー リミテッド | 神経認知障害、慢性疼痛を治療し、炎症を低減させる方法 |
| JP2023505687A (ja) | 2019-12-11 | 2023-02-10 | インスピルナ，インコーポレーテッド | 癌の処置方法 |
| TW202309004A (zh) * | 2021-08-24 | 2023-03-01 | 美商精神醫學公司 | 藉由使用受控和非受控中間體獲取ｍｄｍａ前驅藥之合成途徑 |
| US12384744B2 (en) | 2021-09-29 | 2025-08-12 | Ensysce Biosciences Inc. | Enzyme-cleavable methadone prodrugs and methods of use thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL198169A (OSRAM) * | 1954-06-28 | |||
| US2881113A (en) | 1957-01-29 | 1959-04-07 | Ortho Pharma Corp | Therapeutically active compositions containing amphetamines |
| US2892753A (en) * | 1957-02-26 | 1959-06-30 | Boehringer Sohn Ingelheim | Central nervous system stimulant |
| DE1493824A1 (de) | 1964-01-27 | 1969-05-22 | Hoffmann La Roche | Verfahren zur Herstellung von Aminocarbonsaeureamiden |
| AU773642C (en) | 1997-12-22 | 2006-04-06 | Mundipharma Pty Limited | Opioid agonist/antagonist combinations |
| AU6528400A (en) | 1999-08-23 | 2001-03-19 | David M. Ockert | Triple drug therapy for the treatment of narcotic and alcohol withdrawal symptoms |
| HK1055078A1 (zh) | 2000-06-09 | 2003-12-24 | The Regents Of The University Of California | 使用纳布啡和鸦片拮抗剂治疗疼痛的方法 |
| US6417184B1 (en) | 2000-09-19 | 2002-07-09 | David M. Ockert | Triple drug therapy for the treatment and prevention of acute or chronic pain |
| US7105486B2 (en) * | 2002-02-22 | 2006-09-12 | New River Pharmaceuticals Inc. | Abuse-resistant amphetamine compounds |
| CA2477004C (en) | 2002-02-22 | 2011-05-10 | Thomas Piccariello | Novel sustained release pharmaceutical compounds to prevent abuse of controlled substances |
| EP1613261A4 (en) * | 2003-04-09 | 2011-01-26 | Novo Nordisk As | INTRA-CELLULAR FORMATION OF PEPTIDE CONJUGATES |
| AU2004251647B2 (en) | 2003-05-29 | 2010-01-14 | Takeda Pharmaceutical Company Limited | Abuse resistant amphetamine compounds |
| US20080234206A1 (en) | 2005-09-13 | 2008-09-25 | Shire Llc | Prodrugs of Phentermine |
| AU2007333105A1 (en) | 2006-12-11 | 2008-06-19 | Kempharm, Inc. | Non-standard amino acid conjugates of amphetamine and processes for making and using the same |
| WO2008098151A2 (en) * | 2007-02-08 | 2008-08-14 | Kempharm, Inc. | Polar hydrophilic prodrugs of amphetamine and other stimulants and processes for making and using the same |
-
2007
- 2007-12-10 AU AU2007333105A patent/AU2007333105A1/en not_active Abandoned
- 2007-12-10 ES ES07869098T patent/ES2364865T3/es active Active
- 2007-12-10 CN CNA2007800458802A patent/CN101594778A/zh active Pending
- 2007-12-10 AT AT07869098T patent/ATE509622T1/de not_active IP Right Cessation
- 2007-12-10 CA CA002672138A patent/CA2672138A1/en not_active Abandoned
- 2007-12-10 JP JP2009541507A patent/JP2010512413A/ja not_active Withdrawn
- 2007-12-10 EP EP07869098A patent/EP2101571B1/en not_active Not-in-force
- 2007-12-10 WO PCT/US2007/087028 patent/WO2008073918A1/en not_active Ceased
- 2007-12-10 US US11/953,668 patent/US7776917B2/en active Active
- 2007-12-10 BR BRPI0720105-2A2A patent/BRPI0720105A2/pt not_active IP Right Cessation
-
2009
- 2009-05-25 IL IL198930A patent/IL198930A0/en unknown
- 2009-05-28 US US12/473,903 patent/US20090234018A1/en not_active Abandoned
-
2010
- 2010-07-26 US US12/843,169 patent/US8101661B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2672138A1 (en) | 2008-06-19 |
| AU2007333105A1 (en) | 2008-06-19 |
| IL198930A0 (en) | 2010-02-17 |
| US20100292336A1 (en) | 2010-11-18 |
| CN101594778A (zh) | 2009-12-02 |
| EP2101571A4 (en) | 2010-01-13 |
| US7776917B2 (en) | 2010-08-17 |
| ES2364865T3 (es) | 2011-09-15 |
| US8101661B2 (en) | 2012-01-24 |
| US20080139653A1 (en) | 2008-06-12 |
| EP2101571B1 (en) | 2011-05-18 |
| BRPI0720105A2 (pt) | 2014-10-07 |
| WO2008073918A1 (en) | 2008-06-19 |
| EP2101571A1 (en) | 2009-09-23 |
| US20090234018A1 (en) | 2009-09-17 |
| HK1131518A1 (en) | 2010-01-29 |
| JP2010512413A (ja) | 2010-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE509622T1 (de) | Amphetamin-ornithine konjugate sowie herstellungs-und verwendungsverfahren | |
| ATE552861T1 (de) | Polare hydrophile prodrugs von amphetamin und anderen stimulantien sowie herstellungs- und verwendungsverfahren | |
| WO2007015017A3 (fr) | Nouveaux derives de polyquinoleines et leur utilisation therapeutique | |
| WO2007093627A3 (de) | Biozide zusammensetzung | |
| ATE459611T1 (de) | Kristalline formen von 1-chloro-4-(beta-d- glucopyranos-1-yl)-2-ä4-((r)-tetrahydrofuran-3- yloxy)-benzylü-benzol, zubereitungsverfahren dafür und dessen verwendung zur arzneimittelherstellung | |
| EA201001639A1 (ru) | Композиции и способы их получения и применения | |
| CY1112495T1 (el) | Κυτταροτοξικοι παραγοντες που περιλαμβανουν νεα παραγωγα τομαϋμυκινης | |
| WO2006072393A3 (de) | Sulfonylpyrrolidine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel | |
| EA200700096A1 (ru) | Производные 2-карбамид-4-фенилтиазола, способ их получения и их применение в терапии | |
| DE602007011902D1 (de) | Spiroindolinon-derivate | |
| WO2008017074A3 (en) | Dyes and precursors and conjugates thereof | |
| WO2006136357A3 (de) | Kristalline modifikationen des pyraclostrobins | |
| TW200621313A (en) | Pharmaceutical compositions | |
| WO2009124962A3 (en) | Sulfonamides | |
| EA200900090A1 (ru) | Бензиламины, способ их получения и их применение в качестве противовоспалительных средств | |
| UA94603C2 (ru) | Производные тетрагидронафталина, способ их получения и их применения в качестве ингибиторов воспаления | |
| EA201000039A1 (ru) | Фармацевтическая композиция, включающая солифенацин или его фармацевтически приемлемую соль | |
| WO2007133184A3 (en) | Polypeptides and biosynthetic pathways for the production of stereoisomers of monatin and their precursors | |
| UY29857A1 (es) | Derivados de la 4-amino-quinazolina, su preparación y su aplicación en terapéutica. | |
| DE502006005053D1 (de) | Spritzbare akustikmassen | |
| WO2008107471A3 (en) | Modified hydroxypolymer conjugates with killing effect on tumor cells | |
| MX2009006479A (es) | Derivados de hemicelulosa y estructuras que los emplean. | |
| WO2008023003A8 (de) | Arzneimittelkombinationen zur behandlung von atemwegserkrankungen | |
| WO2007023342A3 (en) | Process of making geminal bisphosphonic acids and pharmaceutically acceptable salts and/or hydrates thereof | |
| ATE528301T1 (de) | Verfahren zur herstellung von substituierten sulfoxidzusammensetzungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |